Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Over-the-counter (OTC) medicinal and healthcare products developer PuraMed BioScience has unveiled the results of clinical trials that found its migraine medication product, LipiGesic M, has "robust efficacy."
Subscribe to our email newsletter
Studies showed that LipiGesic M provides a safe, highly effective OTC solution to migraine pain and performs better than the prescription migraine medications.
LipiGesic M completed the original double-blind, placebo-controlled clinical trial in 2010 and was found to provide relief to around 64% of patients.
PuraMed BioScience CEO Russ Mitchell said that with at least 39 million Americans affected by migraines and LipiGesic M currently retailing for around $19.95 per box, the revenue potential for the product will be substantial.
"Since the performance of LipiGesic M, is more aptly compared to prescription formulations, rather than over-the-counter products, we believe that people currently paying $40 or more for one prescription migraine treatment will turn to LipiGesic M as a highly effective, money-saving alternative that costs approximately $5 per treatment," Mitchell added.
The migraine treatment product is currently available in national retail drugstore chains, such as Walgreens and CVS/pharmacy stores with expansion plans to additional retail chains in the US, as well as International distribution.